Merck Announces 10% Increase in Quarterly Dividend
On July 28, 2026, pharmaceutical giant Merck & Co., Inc. announced an increase in its quarterly dividend from $0.77 to $0.85 per share, a rise of 10.4%. This move marks the 15th consecutive year of dividend increases, making it one of the most stable dividend growers in the US pharmaceutical sector. For investors focused on the "US Stock Dividend Healthcare Pass," this news offers new allocation ideas.
Keytruda New Indication Approval Imminent
Meanwhile, Merck's flagship immuno-oncology drug Keytruda (pembrolizumab) achieved a significant improvement in overall survival (OS) in combination with chemotherapy for non-small cell lung cancer (NSCLC). The US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA), with a decision expected in the fourth quarter of 2026. Analysts predict that if approved, Keytruda's annual sales could exceed $30 billion.
Financial Support Behind Dividend Growth
Merck's Q2 2026 earnings report showed revenue of $14.8 billion, up 8% year-over-year, with Keytruda contributing $7.2 billion. Net profit was $4.3 billion, with ample free cash flow and a healthy dividend payout ratio of around 50%. In the earnings call, management emphasized that the company will continue to reward shareholders through dividends and buybacks while increasing R&D investment to address the patent cliff.
Investment Logic of Pharmaceutical Dividend Stocks
In a low interest rate environment, the pharmaceutical sector is favored by dividend investors for its defensive nature and stable cash flow. However, not all pharmaceutical stocks are suitable for a dividend strategy. Key points to focus on include:
- Patent Expiry Risk: Branded drugs face competition from generics. For example, Merck's core patent for Keytruda will expire after 2028, and the company needs new drugs or acquisitions to fill the revenue gap.
- R&D Pipeline: A robust product pipeline is the foundation for sustained dividend payments. Merck has a presence in metabolism, vaccines, and oncology, with the novel lipid-lowering drug MK-0616 entering Phase III clinical trials.
- Dividend Coverage: A healthy dividend payout ratio (40%-60%) and debt ratio are key indicators. Merck's current net debt/EBITDA ratio is about 1.5x, which is low in the industry.
Industry Cross-Comparison: Which Stocks Deserve Attention?
Besides Merck, other high-dividend stocks in the US pharmaceutical sector include Pfizer (PFE, dividend yield 5.2%), Johnson & Johnson (JNJ, dividend yield 3.1%), and Bristol-Myers Squibb (BMY, dividend yield 4.5%). However, these companies also face their own patent cliffs and regulatory challenges. For example, Pfizer's COVID product revenue has declined sharply, but its oncology and vaccine businesses remain resilient. After Johnson & Johnson's consumer health business spin-off, the profitability of its MedTech segment has improved.
Market Reaction and Valuation Analysis
Following the announcement, Merck's stock rose 2.1% on the day to close at $128, with a trailing P/E ratio of 16x, near its historical median. Compared to the S&P 500 Pharmaceuticals Index's average P/E of 18x, Merck's valuation is reasonable with a margin of safety. For investors seeking stable returns, the current price level is a good opportunity to build positions in batches.
Risk Warning
Investing in the US Stock Dividend Healthcare Pass requires attention to the following risks: First, expectations of Fed rate hikes may affect the relative attractiveness of high-dividend stocks; second, changes in drug pricing policies may squeeze profit margins; third, clinical trial results that fall short of expectations could cause significant stock price volatility. Investors are advised to diversify their allocations and avoid overconcentration in a single stock.
Conclusion
Merck's dividend increase and drug progress once again validate its dual advantages in innovative drugs and shareholder returns. For beginners, the US Stock Dividend Healthcare Pass is a track worth long-term tracking, but dynamic adjustments based on fundamentals and technicals are needed. Duoguping will continue to follow related developments to provide objective and rational investment references for investors.
